VANCOUVER, BC / ACCESSWIRE / September 5, 2019 / Theramed Health Corporation (CSE:TMED, OTCQB:EVAHF) (the “Company”) is pleased to announce the signing of a proposed joint venture agreement with an agent to develop the Asia Pacific market from the Hong Kong SAR (Special Administration Region) for the Company’s licensed cardio-metabolic health system and any developed products under the trade name EGF-Theramed Health.
“Hong Kong is recognized as a leading financial and technology hub, we believe the region is ripe for the continued development of the offerings of the Company’s end to end healthcare systemm,” said CEO, C.K. Cheung.
Theramed continues to execute on its commitment to elevate the human condition through advanced medical solutions, effective health systems and developing wellness products.
THERAMED HEALTH CORPORATION
Email [email protected]
US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news
About THERAMED HEALTH
(CSE: TMED, OTCQB: EVAHF)
Theramed Health Corporation – is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company has recently been focused on utilizing CBD derived from Hemp as a core component. The company through its subsidiaries has assets and technologies involved in extracting and purifying CBD extracts, creating formulations through its key scientists, and with its medical device technology monitoring capabilities. Theramed’s unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated “CBD Health System” for monitoring, dosing, and recording the effects of CBD on your cardiovascular system.
This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, http://thecse.com/en/listings/technology/Theramed-Health-Corporation, and http://www.otcmarkets.com/stock/EVAHF/filings. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
SOURCE: Theramed Health Corporation
View source version on accesswire.com: